Prellis Biologics Pursues Bioprinted Lymph Nodes for Production of COVID-19 Antibodies

Share this Article

Bay Area bioprinting firm Prellis Biologics is researching the use of bioprinted lymph nodes for the production of SARS-CoV-2 antibodies. The idea of using antibodies as a form of preventing an illness is an increasingly popular one, with the idea of injecting a person with pre-existing, artificially manufactured antibodies to an illness before their body has a chance to develop their own either through recovering from a virus or through a vaccine.

Prellis is working to procure a heat-killed virus with a goal of having the sample within 14 days of the project’s start, at which point the company will spend about four weeks printing human lymph nodes and inoculate it, screening for antibodies and sequencing them. After that, the firm suggests that it will be able to find a research center that can gest for viral neutralization and binding affinity of a given antibody before the antibodies will be mass manufactured by a partner company.

Image courtesy of Prellis Biologics.

Prellis isn’t the only one working to make synthetic antibodies to the SARS-CoV-2 virus. In particular, Dr. Jacob Glanville, of Distributed Bio, has received a great deal of attention for promoting the idea. Manufactured antibodies would be injected into frontline workers, who would theoretically be able to fight off the virus with those antibodies for a shorter period of time, maybe eight to 10 weeks.

Synthetic antibodies have been approved by the U.S. Food and Drug Administration (FDA) since 1986, with 570 therapeutic synthetic antibodies studied in clinical trials by commercial companies and 79 FDA approved for the market. About 30 of these are for cancer, with the rest covering asthma, arthritis, psoriasis, Crohn’s disease, transplant rejection, migraine headaches and infectious diseases. Synthetic antibodies to treat viral illnesses, however, is still in the exploratory phase.

The first clinical trials for an antibody therapy for COVID-19 are now underway with an antibody called gimsilumab, which inhibits the growth of a protein that appears in high concentrations in the blood serum of COVID-19 patients and is thought to contribute to the hyper-inflammation in their lungs.

Though we are not experts in antibody production, we should of course be skeptical about the Prellis COVID-19 project because the stakes are so high. From what we know of bioprinting, it has come a long way since its inception in the early 2000s, including a number of recent achievements in the creation of bioprinted organoids, from hearts to kidneys to tumors.

However, the applications of this technology are yet to be fully realized, with even drug testing, one of the more immediately viable uses of bioprinting tissues, still in the exploratory phases. Some animal studies are currently in the works and have great promise, such as the successful transplantation of 3D printed knee cartilage into sheep. With that said, even if Prellis were able to print lymph nodes and see them develop antibodies, there are numerous other variables and obstacles to account for when considering the possibility of successfully mass producing and then deploying these antibodies as a form of therapy.

There is some good reason for hope for the Prellis project to keep in mind. According to Prellis, founder Melanie Matheau was able to create a fully functional human lymph node that produced 11 active antibodies to the Zika virus in 2017, receiving a U.S. patent for the technique in December 2019. The process was repeated with different blood donors, with each sample producing antibodies. The company claims that it can perform the same process to develop antibodies to at least one of the strains of coronavirus currently involved in the global pandemic.

Due to the emergency approval fast-tracking that the FDA is currently implementing, a number of initiatives are being given emergency authorization. This includes potentially problematic ones, such as clinical trials for DNA and RNA vaccines developed by companies partnered with the Defense Advanced Research Projects Agency that were previously unable to get their products licensed for human use, as their vaccines were unable to offer sufficient immunity in human trials. It is possible that, if Prellis is able to achieve its goals, it could be given emergency authorization to perform Clinical I trials.

Share this Article


Recent News

3D Printing Webinar and Virtual Event Roundup, October 25, 2020

3D Printing News Briefs, October 24, 2020: nTopology & Etteplan, DSM, CAR3D Project, MELD Manufacturing



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

NAMIC Global AM Summit 2020: Sustainability, Food 3D Printing, and More

Singapore has been positioning itself as a 3D printing hub for a number of years now. Through the National Additive Manufacturing – Innovation Cluster (NAMIC), it has coordinated investment, meetings,...

Pearce’s Latest Open Source 3D Printer Handles PEKK, PEI for Less than $1,000

In an effort to address, among other things, the need to sterilize 3D-printed personal protection equipment made to fight COVID-19, the lab of Michigan Technological University’s Professor Joshua Pearce has...

3DQue Launches New Automated 3D Print Looping Kit for Ender 3

Vancouver, British Columbia-based startup 3DQue Systems works to automate FFF and FDM 3D printer networks for the purposes of ensuring mass production. The technology it offers is really cool, providing...

Overfunding: REGEMAT 3D Quickly Raises Over €300,000 for Bioprinting Tech

Spanish bioprinter manufacturer REGEMAT 3D has successfully secured its initial €300,000 funding target from more than 390 investors through a crowdfunding platform campaign on Crowdcube. The funding round reached the...


Shop

View our broad assortment of in house and third party products.